248 related articles for article (PubMed ID: 9251604)
1. Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions.
Ganapati R; Pai VV; Shroff HJ; Gandewar K
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):264-6. PubMed ID: 9251604
[No Abstract] [Full Text] [Related]
2. Histological resolution and bacterial clearance with pulse ROM therapy in borderline lepromatous leprosy.
Suneetha S; Reddy R
Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):53-4. PubMed ID: 11480321
[No Abstract] [Full Text] [Related]
3. Efficacy of single-dose ROM therapy plus low-dose convit vaccine as an adjuvant for treatment of paucibacillary leprosy patients with a single skin lesion.
Majumder V; Saha B; Hajra SK; Biswas SK; Saha K
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):283-90. PubMed ID: 11221091
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic prospects for paucibacillary leprosy.
Katoch K
Indian J Lepr; 2000; 72(3):351-61. PubMed ID: 11105276
[No Abstract] [Full Text] [Related]
5. [Recurrent lepromatous leprosy in conventional triple therapy: value of the rifampicin-ofloxacin combination].
Marlier S; Carsuzaa F; De Jaureguiberry JP; Galzin M; Carloz E; Carli P; Chagnon A
Med Trop (Mars); 1995; 55(2):182. PubMed ID: 7565004
[No Abstract] [Full Text] [Related]
6. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
[TBL] [Abstract][Full Text] [Related]
7. Type I reaction in a borderline leprosy case successfully treated with multidrug therapy and ofloxacin.
Asz-Sigall D; López-García L; Neme-Yunes Y; Yuen-Palos R; Vega-Memije ME; Arenas R
Int J Dermatol; 2008 Oct; 47(10):1084-6. PubMed ID: 18986365
[No Abstract] [Full Text] [Related]
8. Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
Ji B
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):391-2. PubMed ID: 9934368
[No Abstract] [Full Text] [Related]
9. Serological monitoring of the response to chemotherapy in leprosy patients.
Roche PW; Britton WJ; Failbus SS; Neupane KD; Theuvenet WJ
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):35-43. PubMed ID: 8326179
[TBL] [Abstract][Full Text] [Related]
10. Histopathologic observations on the persistence of Mycobacterium leprae in the skin of multibacillary leprosy patients under chemotherapy.
Wabitsch KR; Meyers WM
Lepr Rev; 1988 Dec; 59(4):341-6. PubMed ID: 2468983
[No Abstract] [Full Text] [Related]
11. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy.
Grosset JH; Ji BH; Guelpa-Lauras CC; Perani EG; N'Deli LN
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):281-95. PubMed ID: 2198315
[TBL] [Abstract][Full Text] [Related]
12. [How should leprosy be treated?].
Mahé A
Ann Dermatol Venereol; 1998 Dec; 125(12):881-3. PubMed ID: 9922859
[No Abstract] [Full Text] [Related]
13. Two microbiological relapses in a patient with lepromatous leprosy.
Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
[TBL] [Abstract][Full Text] [Related]
14. Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group.
Jamet P; Ji B
Int J Lepr Other Mycobact Dis; 1992 Dec; 60(4):525-35. PubMed ID: 1299707
[TBL] [Abstract][Full Text] [Related]
15. Relapse (reactivation) in borderline tuberculoid (BT) leprosy.
Sehgal VN; Kumar S; Jain S; Bhattacharya SN
J Dermatol; 1998 Jan; 25(1):63-5. PubMed ID: 9519615
[No Abstract] [Full Text] [Related]
16. A bacteriological assessment of multibacillary cases in leprosy colonies after 4 1/2 years of multidrug therapy.
Naik SS; Bhanage ND; Sawant KV; Ganapati R
Indian J Lepr; 1988 Jul; 60(3):393-9. PubMed ID: 3058827
[TBL] [Abstract][Full Text] [Related]
17. Rifampicin-induced erythema nodosum leprosum-like eruption in borderline lepromatous leprosy.
Karthikeyan K; Thappa DM; Kadhiravan T
Indian J Lepr; 2001; 73(2):167-9. PubMed ID: 11579653
[No Abstract] [Full Text] [Related]
18. Leprosy pseudoimbricata: an unusual presentation of steroid-modified borderline lepromatous leprosy.
Kumar S; Mehta H; Aggarwal D; Chatterjee D; Narang T; Dogra S
Int J Dermatol; 2020 Apr; 59(4):e124-e125. PubMed ID: 31957882
[No Abstract] [Full Text] [Related]
19. Controlled clinical trial of two multidrug regimens with and without rifampin in highly bacilliferous BL/LL south Indian patients: a five-year report.
Thomas A; Balakrishnan A; Nagarajan M; Prabhakar R; Tripathy SP; Christian M; Somasundaram PR
Int J Lepr Other Mycobact Dis; 1990 Jun; 58(2):273-80. PubMed ID: 2198314
[TBL] [Abstract][Full Text] [Related]
20. Persister studies in leprosy patients after multi-drug treatment.
Gupta UD; Katoch K; Singh HB; Natrajan M; Katoch VM
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):100-4. PubMed ID: 16830652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
